PAA is a clinical-stage company developing targeted cancer therapeutics for both humans and animals. The company specialises ... in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem, a contract synthetic drug manufacturer forecast to generate Aus$3m in revenues in 2017 at a CAGR of 28%. PAA’s lead drug candidate is Monopantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway - a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs. MPL treatment was well-tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug into Phase 2 clinical trial. read more